SCHEMBL4780346

SCHEMBL4780346

Cc1ccccc1C(N)CO

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.45
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
ACP3 P15309 1/20 0.39
SCN4A P35499 5/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
ACHE P22303 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
GAA P10253 1/20 0.37
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
PDCD1LG2 Q9BQ51 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
CYP3A4 P08684 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17959290 1.00 ESR1 (0.45) ESR1KDM4ECYP1A2ACP3SCN4A
SCHEMBL29746961 1.00 ESR1 (0.45) ESR1KDM4ECYP1A2ACP3SCN4A
Hydrochloric Acid SCHEMBL19305459 0.98 ESR1 (0.43) ESR1KDM4ECYP1A2ACP3SCN4A
Hydrochloric Acid SCHEMBL19305458 0.98 ESR1 (0.43) ESR1KDM4ECYP1A2ACP3SCN4A
SCHEMBL29337470 0.83 TRPA1 (0.40) CYP1A2SCN4AALDH1A1TSHRMAOA
SCHEMBL3383569 0.83 ESR1 (0.42) ESR1CYP1A2ACP3SCN4AALDH1A1
Hydrochloric Acid SCHEMBL382096 0.82 ADRA2A (0.39) CYP1A2SCN4AALDH1A1TSHRMAOA
SCHEMBL3568608 0.82 ALDH1A1 (0.48) KDM4ECYP1A2SCN4AALDH1A1TSHR
SCHEMBL7591099 0.80 ESR1 (0.46) ESR1SCN4AALDH1A1TSHRACHE
SCHEMBL3865062 0.80 ESR1 (0.46) ESR1ACP3SCN4ATSHRACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114948963-B Benzolactam compounds as protein kinase inhibitors 大冢制药株式会社 2025-05-27 CN disclosed
US-12264137-B2 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2025-04-01 US disclosed
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 US disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 EP disclosed
WO-2024118094-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA FOLLEA INTERNATIONAL (US) 2024-06-06 WO disclosed
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11555017-B2 Oxidation base derived from 1-hexyl-4,5-diaminopyrazole, composition containing same and use thereof in oxidation dyeing of keratin fibres L'OREAL (FR) 2023-01-17 US disclosed
CN-114948963-A Protein kinase inhibitor benzolactam compounds 大冢制药株式会社 2022-08-30 CN disclosed
US-20220204461-A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS VALO HEALTH, INC. 2022-06-30 US disclosed
EP-3217967-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA Follea International (US) 2017-09-20 EP disclosed
WO-2017068412-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-27 WO disclosed
WO-2016126724-A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 WO disclosed
US-20160222022-A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS VALO HEALTH, INC. 2016-08-04 US disclosed
WO-2016077744-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA GOREN OFER A (US) 2016-05-19 WO disclosed
WO-2008024634-A1 PYRIMDINE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-28 WO disclosed
EP-1073511-A4 POLYMERIC DIFUNCTIONAL CATIONIC EMOLLIENTS AND CONDITIONERS FOR USE IN COSMETIC, PERSONAL CARE AND HOUSEHOLD PRODUCTS ALZO INC (US) 2005-08-03 EP disclosed
EP-1073511-A1 POLYMERIC DIFUNCTIONAL CATIONIC EMOLLIENTS AND CONDITIONERS FOR USE IN COSMETIC, PERSONAL CARE AND HOUSEHOLD PRODUCTS Alzo, Inc. (US) 2001-02-07 EP disclosed
US-6107352-A CLEANING COMPOUNDS; COSMETICS ALZO, INC. (US) 2000-08-22 US disclosed
WO-1999054027-A1 POLYMERIC DIFUNCTIONAL CATIONIC EMOLLIENTS AND CONDITIONERS FOR USE IN COSMETIC, PERSONAL CARE AND HOUSEHOLD PRODUCTS ALZO, INC. (US) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 ESR1 1975/4885KDM4E 1101/4885CYP1A2 1393/4885
US-20160222022-A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC4, HDAC2 ESR1 4123/4885KDM4E 246/4885CYP1A2 2979/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 ESR1 1975/4885KDM4E 1101/4885CYP1A2 1393/4885
US-12264137-B2 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC4, HDAC2 ESR1 4123/4885KDM4E 246/4885CYP1A2 2979/4885
US-20220204461-A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC4, HDAC2 ESR1 4123/4885KDM4E 246/4885CYP1A2 2979/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 ESR1 1958/4885KDM4E 1095/4885CYP1A2 1397/4885
US-11555017-B2 Oxidation base derived from 1-hexyl-4,5-diaminopyrazole, composition containing same and use thereof in oxidation dyeing of keratin fibres KRT18, ALK, AOC1 ESR1 3986/4885KDM4E 864/4885CYP1A2 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.